Status:

UNKNOWN

The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease

Lead Sponsor:

Istanbul University

Conditions:

Parkinson's Disease

Eligibility:

All Genders

Phase:

PHASE4

Brief Summary

The objective of the study is to assess the effects of rasagiline on cognitive functions in patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned to receive rasag...

Detailed Description

The primary objective of this study is to assess the effects of rasagiline on cognitive deficits in non-demented patients with PD. The secondary objective is to assess affective changes in this patien...

Eligibility Criteria

Inclusion

  • Male and female patients of any age
  • Diagnosis of Idiopathic PD according to the UK Brain Bank Criteria for the clinical diagnosis of PD.
  • Patients with cognitive impairment associated with PD, defined as:
  • Subjective complaints of impaired cognitive functions such as forgetfulness, word finding difficulties or inattentiveness
  • Presence of objectively demonstrable cognitive deficits in at least 2 out of the 4 cognitive domains typically impaired in PD. These include attention, executive functions, memory and visuo-spatial functions. The performance in the following test scores must be 1.5 standard deviations below the mean normative score for age and education of the patient: Digit Span for attention, Letter Fluency test for executive function, Logical Memory Sub-scale from the Wechsler Memory Scale-Revised and Line Orientation Test for visuo-spatial function.
  • Patients with a Hoehn and Yahr stage I-III when "on"
  • Literate patients who are able to follow test instructions

Exclusion

  • Diagnosis of dementia due to PD according to DSM IV criteria
  • Diagnosis of current major depressive episode according to DSM IV criteria
  • Presence of any other neurodegenerative disorder other than PD
  • Presence of any unstable or untreated systemic disorder such as diabetes, cardiac failure, renal failure
  • Use of any prohibited concomitant medication

Key Trial Info

Start Date :

June 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2008

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00696215

Start Date

June 1 2007

End Date

October 1 2008

Last Update

June 12 2008

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Marmara University

Istanbul, Turkey (Türkiye)

2

Raif Cakmur

Izmir, Turkey (Türkiye)